Glycine supplementation resulted in enhanced HBV replication inhibition in vitro and in vivo. The efficacy of glycine can be attributed to its ability to suppress HBV cccDNA expression and increase ...

Simple competitive inhibition of COX-1 by COX-2 inhibitors is thought to occur because of lack of access to the side pocket. [7] Aspirin is unique in comparison with all the other NSAIDs.

Results and Discussion QM/MM Molecular Dynamics Simulations of E-R Complexes QM/MM MD simulations were conducted to elucidate the mechanistic differences in IRAP’s cleavage of the natural substrate ...

DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models ...

Insilico Medicine and collaborators reported promising safety and efficacy results from a Phase IIa trial of Rentosertib (known as ISM001-055), a TNIK inhibitor developed using Insilico's generative ...

FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the T-cell factor (TCF) family of transcription factors, and is currently in clinical development.

Our findings provide the first cocrystal structure of FSP1 in complex with an inhibitor, enhancing our understanding of the mechanism of FSP1 inhibition and enabling future rational medicinal ...

Accropeutics’ drug hit the goals of a phase 2 psoriasis trial in China, prompting the biotech to “accelerate” the TYK2/JAK1 inhibitor’s development.

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. The Big Pharma company discontinued the study testing intra ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque psoriasis, with one producing a PASI90 response in 61% of patients at 52 weeks.